查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1595030

前列腺癌诊断的全球市场

Prostate Cancer Diagnostics
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 89 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

到 2030 年，全球前列腺癌诊断市场预计将达到 137 亿美元

全球前列腺癌诊断市场预计 2023 年为 58 亿美元，预计到 2030 年将达到 137 亿美元，2023 年至 2030 年复合年增长率为 13.1%。初步测试是本报告分析的细分市场之一，预计复合年增长率为 12.4%，到分析期结束时将达到 100 亿美元。在分析期间，验证性测试领域的复合年增长率预计为 15.2%。

美国市场预计15亿美元，中国预计复合年增长率16.9%

到 2023 年，美国前列腺癌诊断市场预计将达到 15 亿美元。中国作为世界第二大经济体，预计2030年市场规模将达33亿美元，2023-2030年分析期间复合年增长率为16.9%。其他值得注意的区域市场包括日本和加拿大，在分析期间预计复合年增长率分别为 9.2% 和 10.8%。在欧洲，德国预计复合年增长率为 10.0%。

全球前列腺癌诊断市场—主要趋势和驱动因素总结

什么是摄护腺癌诊断药物？

前列腺癌诊断是指用于检测、诊断和监测男性前列腺癌的方法和技术。这些诊断方法对于早期发现前列腺癌至关重要，以便及时介入和更有效的治疗。最常见的诊断方法包括前列腺特异性抗原 (PSA) 血液检测、直肠指检 (DRE) 以及先进的影像技术，例如 MRI 和超音波。此外，通常会进行切片检查来确认诊断并确定癌症的阶段。由于前列腺癌是男性最常见的癌症之一，早期准确的诊断对于提高存活率和有效管理治疗计划至关重要。

随着人们对前列腺癌的认识不断提高，尤其是老年男性和有明显家族病史的高风险族群，可靠诊断的需求不断增长。透过提供准确和及时的诊断，前列腺癌诊断不仅有助于快速开始治疗，而且还支持监测治疗后的疾病进展和復发。早期发现可以扩大治疗选择，并且可以显着降低死亡率。随着人口老化和前列腺癌盛行率的增加，对先进诊断工具的需求增加，使前列腺癌诊断市场成为现代医疗保健的重要组成部分。

科技进步将如何改变前列腺癌诊断药物？

分子诊断、诊断影像和人工智慧 (AI) 的技术进步正在彻底改变前列腺癌的诊断，使诊断更加准确、侵入性更小、更快。分子诊断测试，例如基因和生物标记测试，越来越多地用于检测与前列腺癌相关的特定基因突变和蛋白质标记。这些测试有助于确定患者的风险水平，并用于指南个人化治疗决策，使临床医生能够根据癌症的个别特征制定治疗方案。例如，PCA3 测试和 4Kscore 测试等测试收集尿液或血液来检测特定的生物标记物，这可以帮助风险评估并减少侵入性切片检查的需要。

先进的影像技术，例如多参数 MRI 和 PET 扫描，可提供高度详细的影像，可以比传统方法更准确地检测前列腺癌。这些技术可以实现更精确的切片检查目标，这有助于更准确的癌症分期，这对于制定有效的治疗计划至关重要。此外，人工智慧和机器学习演算法越来越多地用于分析来自影像检查和基因测试的大型资料集，透过识别人类观察可能遗漏的模式来提高诊断准确性。事实证明，人工智慧驱动的诊断在风险评估、预测疾病进展和监测治疗反应方面也很有用。这些技术共同正在改变前列腺癌诊断市场，实现早期检测、个人化医疗和改善病患治疗效果。

为什么患者和临床医生越来越多地采用先进的前列腺癌诊断方法？

由于具有更早、更准确的检测、更少的侵入性和个人化治疗选择的潜力，患者和临床医生越来越多地采用先进的前列腺癌诊断方法。 PSA 检测和 DRE 等传统诊断方法的特异性和敏感性有限，常常导致假阳性和不必要的切片检查。分子测试和 MRI 标靶切片检查等先进诊断方法可提供有关癌症风险和分期的更准确信息，使临床医生能够就患者治疗做出更明智的决策。这对于早期或缓慢进展的癌症患者尤其重要，因为它允许主动监测而不是立即干预，从而减少过度治疗副作用的可能性。

对于患者来说，先进的诊断方法可以提供更可靠的结果并减少侵入性手术的需要，让患者安心。液态切片和生物标记测定等非侵入性测试提供了一种侵入性较小的方法来监测癌症进展或復发，使患者能够在最小的不适下控制疾病。从临床角度来看，先进的诊断有助于风险分层，使肿瘤学家能够识别需要积极治疗的高风险患者和那些可以从不太密集的治疗中受益的患者。随着人们对前列腺癌认识的提高，采用先进的诊断工具正在成为患者照护的标准，这与个人化、以患者为中心的医疗保健的更广泛趋势相一致。

推动摄护腺癌诊断市场成长的因素有哪些？

前列腺癌诊断市场的成长受到多种因素的推动，包括人口老化、对前列腺癌认识的提高、诊断技术的进步以及精准医疗的趋势。随着全球前列腺癌高风险老年人口的增加，随着医疗保健提供者努力提高早期检测和介入率，对诊断的需求也在增加。这些人口变化强调了定期筛检和风险评估，特别是在前列腺癌发病率高的国家。此外，宣传宣传活动鼓励更多男性接受定期筛检，有助于提高检出率并增加对准确诊断的需求。

分子诊断和人工智慧等技术进步透过提高诊断程序的准确性、快速性和非侵入性，进一步推动市场成长。精准医学计画根据患者的遗传特征和癌症特征优先考虑治疗，也加速了对基于遗传和生物标记的诊断的需求，从而实现更个人化的癌症治疗方法。此外，监管机构对创新诊断工具的核准不断增加，使临床医生和患者更容易使用它们。这些因素共同推动了前列腺癌诊断市场的强劲成长，并将其定位为对抗癌症的关键发展领域，因为医疗保健系统优先考虑早期检测和个人化治疗。

部分

检验类型（初步检验、确认检验）

受访企业举例（共34家）

  • Abbott
  • Beckman Coulter, Inc.
  • BioMerieux, Inc.
  • Diasorin SPA
  • Roche Diagnostics Corporation
  • Mdxhealth
  • Myriad Genetic, Inc.
  • Opko Health, Inc.
  • Siemens Healthineers USA
  • Ipsen Pharma

目录

第一章调查方法

第 2 章执行摘要

  • 市场概况
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 其他亚太地区
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他中东地区
  • 非洲

第四章 比赛

简介目录
Product Code: MCP22652

Global Prostate Cancer Diagnostics Market to Reach US$13.7 Billion by 2030

The global market for Prostate Cancer Diagnostics estimated at US$5.8 Billion in the year 2023, is expected to reach US$13.7 Billion by 2030, growing at a CAGR of 13.1% over the analysis period 2023-2030. Preliminary Test, one of the segments analyzed in the report, is expected to record a 12.4% CAGR and reach US$10.0 Billion by the end of the analysis period. Growth in the Confirmatory Test segment is estimated at 15.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.5 Billion While China is Forecast to Grow at 16.9% CAGR

The Prostate Cancer Diagnostics market in the U.S. is estimated at US$1.5 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$3.3 Billion by the year 2030 trailing a CAGR of 16.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.2% and 10.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.0% CAGR.

Global Prostate Cancer Diagnostics Market - Key Trends & Drivers Summarized

What is Prostate Cancer Diagnostics, and Why is It Essential for Early Detection?

Prostate cancer diagnostics refers to the methods and technologies used to detect, diagnose, and monitor prostate cancer in men. These diagnostics are critical in identifying prostate cancer in its early stages, allowing for timely intervention and more effective treatment. The most common diagnostic methods include prostate-specific antigen (PSA) blood tests, digital rectal exams (DRE), and advanced imaging techniques like MRI and ultrasound. Additionally, biopsies are often used to confirm diagnosis and determine the stage of the cancer. Given that prostate cancer is one of the most common cancers among men, early and accurate diagnosis is essential to improving survival rates and managing treatment plans effectively.

The need for reliable diagnostics is increasingly important as awareness around prostate cancer grows, particularly among high-risk populations such as older men and those with a family history of the disease. By providing accurate and timely diagnoses, prostate cancer diagnostics not only help in initiating prompt treatment but also support monitoring of the disease's progression or recurrence after treatment. Early detection can lead to a wider range of treatment options and significantly reduce mortality rates. As the population ages and the prevalence of prostate cancer rises, demand for advanced diagnostic tools is increasing, making the prostate cancer diagnostics market a crucial component of modern healthcare.

How Are Technological Advancements Transforming Prostate Cancer Diagnostics?

Technological advancements in molecular diagnostics, imaging, and artificial intelligence (AI) are revolutionizing prostate cancer diagnostics, enabling more precise, less invasive, and faster diagnosis. Molecular diagnostic tests, such as genetic and biomarker testing, are increasingly used to detect specific genetic mutations or protein markers associated with prostate cancer. These tests help determine a patient’s risk level and may be used to guide personalized treatment decisions, allowing clinicians to tailor therapies based on the individual characteristics of the cancer. For example, tests like the PCA3 test and 4Kscore test use urine or blood samples to detect specific biomarkers, aiding in risk assessment and reducing the need for invasive biopsies.

Advanced imaging techniques, including multiparametric MRI and PET scans, provide highly detailed visuals that can detect prostate cancer with greater accuracy than traditional methods. These technologies allow for more precise targeting in biopsies and help in staging the cancer more accurately, which is essential for planning effective treatment. Additionally, AI and machine learning algorithms are now being used to analyze large datasets from imaging and genetic tests, enhancing diagnostic accuracy by identifying patterns that may be missed by human observation. AI-driven diagnostics are also proving valuable in risk assessment, predicting disease progression, and monitoring response to treatment. Together, these technologies are transforming the prostate cancer diagnostics market, enabling early detection, personalized care, and improved patient outcomes.

Why Are Patients and Clinicians Increasingly Adopting Advanced Prostate Cancer Diagnostics?

Patients and clinicians are increasingly adopting advanced prostate cancer diagnostics due to their potential for earlier and more accurate detection, reduced invasiveness, and personalized treatment options. Traditional diagnostics, such as PSA tests and DREs, have limitations in specificity and sensitivity, often leading to false positives or unnecessary biopsies. Advanced diagnostics, like molecular tests and MRI-targeted biopsies, provide more precise information on cancer risk and stage, enabling clinicians to make better-informed decisions about patient care. This is particularly important for patients with early-stage or slow-growing cancers, as it allows for active surveillance rather than immediate intervention, reducing potential side effects of overtreatment.

For patients, advanced diagnostics offer peace of mind by providing more reliable results and reducing the need for invasive procedures. Non-invasive tests, such as liquid biopsies and biomarker assays, offer a less intrusive way to monitor cancer progression or recurrence, allowing patients to manage their condition with minimal discomfort. From a clinical perspective, advanced diagnostics facilitate risk stratification, enabling oncologists to identify high-risk patients who require aggressive treatment and those who may benefit from less intensive approaches. As awareness around prostate cancer grows, the adoption of sophisticated diagnostic tools is becoming standard in patient care, aligning with a broader trend towards personalized and patient-centered healthcare.

What Factors Drive Growth in the Prostate Cancer Diagnostics Market?

The growth of the prostate cancer diagnostics market is driven by several factors, including the aging population, increased awareness of prostate cancer, advancements in diagnostic technology, and the trend towards precision medicine. With a growing global elderly population—who are at higher risk for prostate cancer—the demand for diagnostics is rising as healthcare providers strive to improve early detection and intervention rates. This demographic shift has intensified the focus on regular screenings and risk assessments, especially in countries with high prostate cancer prevalence. Additionally, increased awareness campaigns have encouraged more men to undergo routine screenings, contributing to greater detection rates and driving the need for accurate diagnostics.

Advancements in technology, such as molecular diagnostics and AI, are further propelling market growth by improving the accuracy, speed, and non-invasiveness of diagnostic procedures. Precision medicine initiatives, which prioritize treatments based on a patient’s genetic profile and cancer characteristics, have also accelerated demand for genetic and biomarker-based diagnostics, supporting a more personalized approach to cancer care. Moreover, regulatory agencies are increasingly approving innovative diagnostic tools, making them more accessible to clinicians and patients. As healthcare systems prioritize early detection and personalized treatment, these factors are collectively driving robust growth in the prostate cancer diagnostics market, positioning it as a key area of development in the fight against cancer.

SCOPE OF STUDY:

The report analyzes the Prostate Cancer Diagnostics market in terms of US$ Million by the following Test Type, and Geographic Regions/Countries:

Segments:

Test Type (Preliminary, Confirmatory)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • Abbott
  • Beckman Coulter, Inc.
  • BioMerieux, Inc.
  • Diasorin S.P.A.
  • Roche Diagnostics Corporation
  • Mdxhealth
  • Myriad Genetic, Inc.
  • Opko Health, Inc.
  • Siemens Healthineers USA
  • Ipsen Pharma

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Prostate Cancer Diagnostics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Prostate Cancer Globally Drives Demand for Advanced and Accurate Diagnostic Solutions
    • Increased Focus on Early Detection and Screening Spurs Market for Prostate-Specific Antigen (PSA) Testing
    • Growth in Personalized Medicine and Targeted Therapies Expands Demand for Genomic and Biomarker-Based Diagnostics
    • Advances in Imaging Technologies, Including MRI and PET Scans, Enhance Accuracy in Prostate Cancer Diagnosis
    • Increased Demand for Non-Invasive Testing Options Supports Development of Liquid Biopsy and Urine-Based Diagnostics
    • Growth in Awareness Campaigns and Screening Programs Elevates Market Demand for Accessible Diagnostic Tools
    • Expansion of AI and Machine Learning in Radiology Enhances Detection Accuracy and Reduces Diagnostic Errors
    • High Demand for Risk Stratification and Disease Progression Monitoring Fuels Use of Advanced Diagnostic Solutions
    • Rising Demand for Digital Pathology and Telemedicine Platforms Expands Accessibility of Prostate Cancer Diagnostics
    • Increased Focus on Minimally Invasive Biopsy Techniques Drives Adoption of MRI-Guided and Targeted Biopsies
    • Advances in Biomarker Discovery and Validation Strengthen Market for Predictive and Prognostic Testing
    • Growth of Immunohistochemistry (IHC) and Genetic Testing in Clinical Practice Expands Diagnostic Capabilities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Prostate Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Prostate Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Preliminary by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Preliminary by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Preliminary by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Confirmatory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Confirmatory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Confirmatory by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Prostate Cancer Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Prostate Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 11: USA Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 12: USA Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: USA 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 14: Canada Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 15: Canada Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: Canada 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • JAPAN
    • Prostate Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 17: Japan Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 18: Japan Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: Japan 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • CHINA
    • Prostate Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 20: China Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: China Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: China 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • EUROPE
    • Prostate Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 23: Europe Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: Europe Historic Review for Prostate Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: Europe 16-Year Perspective for Prostate Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • FRANCE
    • Prostate Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 29: France Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: France Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: France 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • GERMANY
    • Prostate Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 32: Germany Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Germany Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Germany 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 35: Italy Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Italy Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Italy 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Prostate Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 38: UK Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: UK Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: UK 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 41: Spain Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Spain Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Spain 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 44: Russia Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Russia Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Russia 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Rest of Europe Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Rest of Europe 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Prostate Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 51: Asia-Pacific Historic Review for Prostate Cancer Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Asia-Pacific 16-Year Perspective for Prostate Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Prostate Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 56: Australia Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Australia Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Australia 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • INDIA
    • Prostate Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 59: India Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: India Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: India 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 62: South Korea Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: South Korea Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: South Korea 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 65: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Rest of Asia-Pacific Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Rest of Asia-Pacific 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Prostate Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 68: Latin America Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 69: Latin America Historic Review for Prostate Cancer Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Latin America 16-Year Perspective for Prostate Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 74: Argentina Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Argentina Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Argentina 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 77: Brazil Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Brazil Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Brazil 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 80: Mexico Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Mexico Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Mexico 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 83: Rest of Latin America Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Rest of Latin America Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Rest of Latin America 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Prostate Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 86: Middle East Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 87: Middle East Historic Review for Prostate Cancer Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Middle East 16-Year Perspective for Prostate Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 92: Iran Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Iran Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Iran 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 95: Israel Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Israel Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Israel 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 98: Saudi Arabia Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Saudi Arabia Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Saudi Arabia 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 101: UAE Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: UAE Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: UAE 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 104: Rest of Middle East Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Rest of Middle East Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Rest of Middle East 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • AFRICA
    • Prostate Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 107: Africa Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Africa Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Africa 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030

IV. COMPETITION